China gives conditional approval to Sinopharm vaccine

China has given conditional approval to a coronavirus vaccine developed by state-owned Sinopharm. The vaccine is the first one approved for general use in China. The vaccine is an inactivated, two-dose vaccine from the Beijing Institute of Biological Products, a subsidiary of state-owned conglomerate Sinopharm.

China has given conditional approval to a coronavirus vaccine developed by state-owned Sinopharm. The vaccine is the first one approved for general use in China. Chen Shifei, the deputy commissioner of China's Medical Production Administration, said at a news conference Thursday that the decision had been made the previous night. The vaccine is an inactivated, two-dose vaccine from the Beijing Institute of Biological Products, a subsidiary of state-owned conglomerate Sinopharm. The company announced Wednesday that preliminary data from last-stage trials had shown it to be 79.3 per cent effective

Sinopharm is one of at least five Chinese developers that are in a global race to create vaccines for the disease that has killed more than 1.8 million people.